Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C8 | P10632 | 1/20 | 0.31 |
| ▸ | BCL2 | P10415 | 1/20 | 0.30 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25254199 | 1.00 | CYP2C8 (0.31) | CYP2C8BCL2BCL2L1 | |
| SCHEMBL25248298 | 0.93 | CYP2C8 (0.35) | CYP2C8BCL2BCL2L1 | |
| SCHEMBL29897089 | 0.93 | CYP2C8 (0.35) | CYP2C8BCL2BCL2L1 | |
| SCHEMBL29897071 | 0.92 | PDE6D (0.30) | BCL2BCL2L1 | |
| SCHEMBL25249630 | 0.92 | PDE6D (0.30) | BCL2BCL2L1 | |
| SCHEMBL25295798 | 0.91 | BAD (0.33) | CYP2C8BCL2BCL2L1 | |
| SCHEMBL29897059 | 0.91 | BAD (0.33) | CYP2C8BCL2BCL2L1 | |
| SCHEMBL25786208 | 0.88 | MARK3 (0.34) | CYP2C8BCL2BCL2L1 | |
| SCHEMBL25290938 | 0.86 | BAD (0.35) | BCL2BCL2L1 | |
| SCHEMBL29897046 | 0.86 | BAD (0.35) | BCL2BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691989-B2 | Macrocyclic indoles as Mcl-1 inhibitors | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
| US-20220340595-A1 | MACROCYCLIC INDOLES AS MCL-1 INHIBITORS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340595-A1 | MACROCYCLIC INDOLES AS MCL-1 INHIBITORS | MCL1, BCL2A1, BCL2L1 | CYP2C8 3462/4885BCL2 10/4885BCL2L1 3/4885 |
| US-11691989-B2 | Macrocyclic indoles as Mcl-1 inhibitors | MCL1, BCL2A1, BCL2L1 | CYP2C8 3462/4885BCL2 10/4885BCL2L1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.